

Richard D Kennedy

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9449437/publications.pdf>

Version: 2024-02-01

97
papers

5,178
citations

109264

35
h-index

85498

71
g-index

97
all docs

97
docs citations

97
times ranked

8486
citing authors

#	ARTICLE	IF	CITATIONS
1	Activation of a cGAS-STING-mediated immune response predicts response to neoadjuvant chemotherapy in early breast cancer. <i>British Journal of Cancer</i> , 2022, 126, 247-258.	2.9	14
2	A comprehensive systematic review and network meta-analysis: the role of anti-angiogenic agents in advanced epithelial ovarian cancer. <i>Scientific Reports</i> , 2022, 12, 3803.	1.6	7
3	Multioomic Characterization of High-Grade Serous Ovarian Carcinoma Enables High-Resolution Patient Stratification. <i>Clinical Cancer Research</i> , 2022, 28, 3546-3556.	3.2	5
4	In-depth Clinical and Biological Exploration of DNA Damage Immune Response as a Biomarker for Oxaliplatin Use in Colorectal Cancer. <i>Clinical Cancer Research</i> , 2021, 27, 288-300.	3.2	13
5	The clinical and molecular significance associated with STING signaling in breast cancer. <i>Npj Breast Cancer</i> , 2021, 7, 81.	2.3	21
6	A DNA-damage immune response assay combined with PET biomarkers predicts response to neo-adjuvant chemotherapy and survival in oesophageal adenocarcinoma. <i>Scientific Reports</i> , 2021, 11, 13061.	1.6	0
7	ATM Kinase Inhibition Preferentially Sensitises PTEN-Deficient Prostate Tumour Cells to Ionising Radiation. <i>Cancers</i> , 2021, 13, 79.	1.7	2
8	Results of a phase II clinical trial of 6-mercaptopurine (6MP) and methotrexate in patients with BRCA-defective tumours. <i>British Journal of Cancer</i> , 2020, 122, 483-490.	2.9	8
9	A Novel Role for Cathepsin S as a Potential Biomarker in Triple Negative Breast Cancer. <i>Journal of Oncology</i> , 2019, 2019, 1-12.	0.6	16
10	Validation of the DNA Damage Immune Response Signature in Patients With Triple-Negative Breast Cancer From the SWOG 9313c Trial. <i>Journal of Clinical Oncology</i> , 2019, 37, 3484-3492.	0.8	30
11	Defining the molecular evolution of extrauterine high grade serous carcinoma. <i>Gynecologic Oncology</i> , 2019, 155, 305-317.	0.6	17
12	DNA Repair Deficiency in Breast Cancer: Opportunities for Immunotherapy. <i>Journal of Oncology</i> , 2019, 2019, 1-14.	0.6	18
13	PDLIM2 Is a Marker of Adhesion and β -Catenin Activity in Triple-Negative Breast Cancer. <i>Cancer Research</i> , 2019, 79, 2619-2633.	0.4	14
14	Immune activation by DNA damage predicts response to chemotherapy and survival in oesophageal adenocarcinoma. <i>Gut</i> , 2019, 68, 1918-1927.	6.1	18
15	Development of PARP Inhibitors for BRCA-Deficient Epithelial Ovarian Cancer. , 2019, , 521-532.		2
16	Targeting of survivin to overcome cisplatin resistance in esophageal adenocarcinoma.. <i>Journal of Clinical Oncology</i> , 2019, 37, e15535-e15535.	0.8	1
17	Defining an IBD-like subgroup in consensus molecular subgroups of colorectal cancer and transcriptomic biomarker development for at-risk patients.. <i>Journal of Clinical Oncology</i> , 2019, 37, e15142-e15142.	0.8	0
18	Consensus gene expression analysis to identify key hallmarks of cancer in malignant melanoma.. <i>Journal of Clinical Oncology</i> , 2019, 37, e21045-e21045.	0.8	0

#	ARTICLE	IF	CITATIONS
19	FES-related tyrosine kinase activates the insulin-like growth factor-1 receptor at sites of cell adhesion. <i>Oncogene</i> , 2018, 37, 3131-3150.	2.6	22
20	Automated Tumour Recognition and Digital Pathology Scoring Unravels New Role for PD-L1 in Predicting Good Outcome in ER-/HER2+ Breast Cancer. <i>Journal of Oncology</i> , 2018, 2018, 1-14.	0.6	44
21	The musculoskeletal consequences of latissimus dorsi breast reconstruction in women following mastectomy for breast cancer. <i>PLoS ONE</i> , 2018, 13, e0202859.	1.1	9
22	Abstract 3787: Exploring the effect of chemotherapies on STING-dependent cytokine release. <i>Cancer Research</i> , 2018, 78, 3787-3787.	0.4	2
23	Platinum based chemotherapy selects for PDGFR $\hat{\pm}$ dependent angiogenesis.. <i>Journal of Clinical Oncology</i> , 2018, 36, 5578-5578.	0.8	1
24	Activation of MAPK signalling results in resistance to saracatinib (AZD0530) in ovarian cancer. <i>Oncotarget</i> , 2018, 9, 4722-4736.	0.8	22
25	Glucose transporter 1 expression as a marker of prognosis in oesophageal adenocarcinoma. <i>Oncotarget</i> , 2018, 9, 18518-18528.	0.8	13
26	Pan-cancer mesenchymal assay to predict response to MEK inhibitors.. <i>Journal of Clinical Oncology</i> , 2018, 36, 12111-12111.	0.8	0
27	Reply to L. Casadaban et al. <i>Journal of Clinical Oncology</i> , 2017, 35, 1373-1374.	0.8	0
28	Molecular Subgroup of Primary Prostate Cancer Presenting with Metastatic Biology. <i>European Urology</i> , 2017, 72, 509-518.	0.9	26
29	Activation of STING-Dependent Innate Immune Signaling By S-Phase-Specific DNA Damage in Breast Cancer. <i>Journal of the National Cancer Institute</i> , 2017, 109, djw199.	3.0	338
30	Impact of DNA repair deficiency signature on outcomes in triple negative breast cancer (TNBC) patients treated with AC chemotherapy (SWOG S9313).. <i>Journal of Clinical Oncology</i> , 2017, 35, 529-529.	0.8	2
31	Development of a pan-cancer 15 gene expression signature to detect a subgroup driven by EMT/MAPK signalling.. <i>Journal of Clinical Oncology</i> , 2017, 35, 11616-11616.	0.8	0
32	PD-L1 expression and response to neo-adjuvant chemotherapy in esophageal adenocarcinoma.. <i>Journal of Clinical Oncology</i> , 2017, 35, 4023-4023.	0.8	1
33	Assessment of conditional survival probability in resected esophageal adenocarcinoma.. <i>Journal of Clinical Oncology</i> , 2017, 35, 4030-4030.	0.8	0
34	Association of a DNA damage response deficiency (DDR) assay with prognosis in resected esophageal and gastric adenocarcinoma.. <i>Journal of Clinical Oncology</i> , 2017, 35, 4026-4026.	0.8	0
35	Clinical Application of Poly(ADP-Ribose) Polymerase Inhibitors in High-Grade Serous Ovarian Cancer. <i>Oncologist</i> , 2016, 21, 586-593.	1.9	23
36	Molecular Subtypes and Personalized Therapy in Metastatic Colorectal Cancer. <i>Current Colorectal Cancer Reports</i> , 2016, 12, 141-150.	1.0	40

#	ARTICLE	IF	CITATIONS
37	Delivering a research-enabled multistakeholder partnership for enhanced patient care at a population level: The Northern Ireland Comprehensive Cancer Program. <i>Cancer</i> , 2016, 122, 664-673.	2.0	5
38	Association Between Results of a Gene Expression Signature Assay and Recurrence-Free Interval in Patients With Stage II Colon Cancer in Cancer and Leukemia Group B 9581 (Alliance). <i>Journal of Clinical Oncology</i> , 2016, 34, 3047-3053.	0.8	51
39	When the guardian becomes the enemy: Targeting ATM in PTEN-deficient cancers. <i>Molecular and Cellular Oncology</i> , 2016, 3, e1053595.	0.3	5
40	The role of PTEN as a cancer biomarker. <i>Oncoscience</i> , 2016, 3, 54-55.	0.9	15
41	A BRCA1 deficient, NF- κ B driven immune signal predicts good outcome in triple negative breast cancer. <i>Oncotarget</i> , 2016, 7, 19884-19896.	0.8	30
42	Orthogonal targeting of EGFRvIII expressing glioblastomas through simultaneous EGFR and PLK1 inhibition. <i>Oncotarget</i> , 2015, 6, 11751-11767.	0.8	9
43	Clinical Tumor Staging of Adenocarcinoma of the Esophagus and Esophagogastric Junction. <i>Journal of Clinical Oncology</i> , 2015, 33, 1088-1088.	0.8	5
44	Integrated molecular pathology: the Belfast model. <i>Drug Discovery Today</i> , 2015, 20, 1451-1454.	3.2	6
45	STAT3 regulated ARF expression suppresses prostate cancer metastasis. <i>Nature Communications</i> , 2015, 6, 7736.	5.8	136
46	Mechanistic Rationale to Target PTEN-Deficient Tumor Cells with Inhibitors of the DNA Damage Response Kinase ATM. <i>Cancer Research</i> , 2015, 75, 2159-2165.	0.4	58
47	PICan: An integromics framework for dynamic cancer biomarker discovery. <i>Molecular Oncology</i> , 2015, 9, 1234-1240.	2.1	15
48	Identification and Validation of an Anthracycline/Cyclophosphamide-Based Chemotherapy Response Assay in Breast Cancer. <i>Journal of the National Cancer Institute</i> , 2014, 106, djt335.	3.0	91
49	NF- κ B is a critical mediator of BRCA1-induced chemoresistance. <i>Oncogene</i> , 2014, 33, 713-723.	2.6	41
50	Association of a DNA damage response deficiency (DDR) assay and prognosis in early-stage esophageal adenocarcinoma. <i>Journal of Clinical Oncology</i> , 2014, 32, 4015-4015.	0.8	3
51	Molecular subgroup of high-grade serous ovarian cancer (HGSOC) as a predictor of outcome following bevacizumab. <i>Journal of Clinical Oncology</i> , 2014, 32, 5502-5502.	0.8	71
52	Association between ColDx assay result and recurrence-free interval in stage II colon cancer patients on CALGB (Alliance) 9581. <i>Journal of Clinical Oncology</i> , 2014, 32, 455-455.	0.8	4
53	A preoperative clinical staging and metabolic imaging model to predict prognosis in early-stage esophageal adenocarcinoma. <i>Journal of Clinical Oncology</i> , 2014, 32, 63-63.	0.8	1
54	Discovery of prognostic and predictive tissue biomarkers in patients with resectable esophageal cancer. <i>Journal of Clinical Oncology</i> , 2014, 32, 45-45.	0.8	0

#	ARTICLE	IF	CITATIONS
55	Academic medicine - revolution, evolution or extinction?. <i>Ulster Medical Journal</i> , 2014, 83, 141-5.	0.2	4
56	Potential of Inflammatory CXCL8 Signalling Sustains Cell Survival in PTEN-deficient Prostate Carcinoma. <i>European Urology</i> , 2013, 64, 177-188.	0.9	67
57	Model selection for prognostic time-to-event gene signature discovery with applications in early breast cancer data. <i>Statistical Applications in Genetics and Molecular Biology</i> , 2013, 12, 619-35.	0.2	2
58	BRCA1 is a key regulator of breast differentiation through activation of Notch signalling with implications for anti-endocrine treatment of breast cancers. <i>Nucleic Acids Research</i> , 2013, 41, 8601-8614.	6.5	44
59	Identification and validation of an assay predictive of response and prognosis following anthracycline-based chemotherapy for early breast cancer.. <i>Journal of Clinical Oncology</i> , 2013, 31, TPS11120-TPS11120.	0.8	0
60	Long-range Transcriptome Sequencing Reveals Cancer Cell Growth Regulatory Chimeric mRNA. <i>Neoplasia</i> , 2012, 14, 1087-49.	2.3	19
61	Implications for Powering Biomarker Discovery Studies. <i>Journal of Molecular Diagnostics</i> , 2012, 14, 130-139.	1.2	7
62	BRCA1 and GATA3 corepress FOXC1 to inhibit the pathogenesis of basal-like breast cancers. <i>Oncogene</i> , 2012, 31, 3667-3678.	2.6	77
63	Expression of the SEPT9_i4 isoform confers resistance to microtubule-interacting drugs. <i>Cellular Oncology (Dordrecht)</i> , 2012, 35, 85-93.	2.1	25
64	BRCA1 is both a prognostic and predictive biomarker of response to chemotherapy in sporadic epithelial ovarian cancer. <i>Gynecologic Oncology</i> , 2011, 123, 492-498.	0.6	62
65	Human MutS and FANCM complexes function as redundant DNA damage sensors in the Fanconi Anemia pathway. <i>DNA Repair</i> , 2011, 10, 1203-1212.	1.3	26
66	The $\hat{\tau}$ Np63 Proteins Are Key Allies of BRCA1 in the Prevention of Basal-Like Breast Cancer. <i>Cancer Research</i> , 2011, 71, 1933-1944.	0.4	35
67	Development and Independent Validation of a Prognostic Assay for Stage II Colon Cancer Using Formalin-Fixed Paraffin-Embedded Tissue. <i>Journal of Clinical Oncology</i> , 2011, 29, 4620-4626.	0.8	178
68	Upregulation of Fanconi Anemia DNA Repair Genes in Melanoma Compared with Non-Melanoma Skin Cancer. <i>Journal of Investigative Dermatology</i> , 2011, 131, 2139-2142.	0.3	18
69	Developing mRNA-based biomarkers from formalin-fixed paraffin-embedded tissue. <i>Personalized Medicine</i> , 2010, 7, 205-211.	0.8	6
70	BRCA1 transcriptionally regulates genes associated with the basal-like phenotype in breast cancer. <i>Breast Cancer Research and Treatment</i> , 2010, 122, 721-731.	1.1	68
71	T-box 2 represses NDRG1 through an EGR1-dependent mechanism to drive the proliferation of breast cancer cells. <i>Oncogene</i> , 2010, 29, 3252-3262.	2.6	57
72	Targeting EGFR Induced Oxidative Stress by PARP1 Inhibition in Glioblastoma Therapy. <i>PLoS ONE</i> , 2010, 5, e10767.	1.1	59

#	ARTICLE	IF	CITATIONS
73	Prognostic and Predictive Biomarkers in Resected Colon Cancer: Current Status and Future Perspectives for Integrating Genomics into Biomarker Discovery. <i>Oncologist</i> , 2010, 15, 390-404.	1.9	155
74	The Complex Relationship between BRCA1 and ER α in Hereditary Breast Cancer. <i>Clinical Cancer Research</i> , 2009, 15, 1514-1518.	3.2	58
75	Tissue Biomarker Development in a Multicentre Trial Context: a Feasibility Study on the PETACC3 Stage II and III Colon Cancer Adjuvant Treatment Trial. <i>Clinical Cancer Research</i> , 2009, 15, 5528-5533.	3.2	30
76	BRCA1 and implications for response to chemotherapy in ovarian cancer. <i>Gynecologic Oncology</i> , 2009, 113, 134-142.	0.6	78
77	Cdk1 Participates in BRCA1-Dependent S Phase Checkpoint Control in Response to DNA Damage. <i>Molecular Cell</i> , 2009, 35, 327-339.	4.5	109
78	CHK1 inhibition as a strategy for targeting fanconi anemia (FA) DNA repair pathway deficient tumors. <i>Molecular Cancer</i> , 2009, 8, 24.	7.9	103
79	RNA expression analysis from formalin fixed paraffin embedded tissues. <i>Histochemistry and Cell Biology</i> , 2008, 130, 435-445.	0.8	169
80	Generation of a non-small cell lung cancer transcriptome microarray. <i>BMC Medical Genomics</i> , 2008, 1, 20.	0.7	18
81	Chk1 Suppresses a Caspase-2 Apoptotic Response to DNA Damage that Bypasses p53, Bcl-2, and Caspase-3. <i>Cell</i> , 2008, 133, 864-877.	13.5	295
82	Chk1-Mediated Phosphorylation of FANCD1 Is Required for the Fanconi Anemia/BRCA Pathway. <i>Molecular and Cellular Biology</i> , 2007, 27, 3098-3108.	1.1	132
83	Fanconi anemia pathway-deficient tumor cells are hypersensitive to inhibition of ataxia telangiectasia mutated. <i>Journal of Clinical Investigation</i> , 2007, 117, 1440-1449.	3.9	155
84	Chemosensitization to cisplatin by inhibitors of the Fanconi anemia/BRCA pathway. <i>Molecular Cancer Therapeutics</i> , 2006, 5, 952-961.	1.9	190
85	DNA Repair Pathways in Clinical Practice: Lessons From Pediatric Cancer Susceptibility Syndromes. <i>Journal of Clinical Oncology</i> , 2006, 24, 3799-3808.	0.8	262
86	Modifier Genetics in Zebrafish Identify Chk1 and an Associated Survival Pathway as Targets for Pharmacotherapy of MDS/AML with P53 Mutations.. <i>Blood</i> , 2006, 108, 1432-1432.	0.6	0
87	The 2,5 oligoadenylate synthetase/RNaseL pathway is a novel effector of BRCA1- and interferon- β -mediated apoptosis. <i>Oncogene</i> , 2005, 24, 5492-5501.	2.6	53
88	BRCA1 and c-Myc Associate to Transcriptionally Repress Psoriasin, a DNA Damage-Inducible Gene. <i>Cancer Research</i> , 2005, 65, 10265-10272.	0.4	76
89	The Fanconi Anemia/BRCA pathway: new faces in the crowd. <i>Genes and Development</i> , 2005, 19, 2925-2940.	2.7	349
90	Functional Interaction between FANCD2 and ATM in the DNA Damage Response.. <i>Blood</i> , 2005, 106, 181-181.	0.6	0

#	ARTICLE	IF	CITATIONS
91	BRCA1 Interacts with and Is Required for Paclitaxel-Induced Activation of Mitogen-Activated Protein Kinase Kinase Kinase 3. <i>Cancer Research</i> , 2004, 64, 4148-4154.	0.4	46
92	The Role of BRCA1 in the Cellular Response to Chemotherapy. <i>Journal of the National Cancer Institute</i> , 2004, 96, 1659-1668.	3.0	399
93	The biology of breast carcinoma. <i>Cancer</i> , 2003, 98, 1327-1328.	2.0	1
94	Role played by BRCA1 in regulating the cellular response to stress. <i>Biochemical Society Transactions</i> , 2003, 31, 257-262.	1.6	17
95	BRCA1 functions as a differential modulator of chemotherapy-induced apoptosis. <i>Cancer Research</i> , 2003, 63, 6221-8.	0.4	339
96	BRCA1 : mechanisms of inactivation and implications for management of patients. <i>Lancet, The</i> , 2002, 360, 1007-1014.	6.3	115
97	Gene therapy for breast and ovarian cancer. , 2002, , 372-383.		0